To report a rare case of coexisting Smoldering Waldenström Macroglobulinemia (SWM) and Myelodysplastic Syndrome (MDS) and review existing literature on this coexistence, highlighting its clinical significance.
Key Findings:
Clonal evolution documented from 2.5% blasts (MDS with low blasts) to 6% blasts (MDS with increased blasts-1) and ultimately to AML (66% blasts), emphasizing the need for vigilant monitoring.
Emergence of FLT3-ITD mutation drove rapid progression to AML after MDS remission, indicating a critical area for future research.
Persistent cytopenias during ibrutinib therapy were due to MDS progression rather than SWM, underscoring the importance of reevaluation in similar clinical scenarios.
Interpretation:
The case emphasizes the importance of reevaluation in patients with persistent cytopenias and highlights the potential for clonal evolution in hematological malignancies, which may inform future treatment strategies.
Limitations:
The rarity of the coexistence of SWM and MDS limits generalizability and may introduce biases in case reporting.
Only a few cases have been reported in the literature, making it difficult to draw broad conclusions about treatment efficacy.
Conclusion:
This case illustrates the complexities of diagnosing and managing coexisting hematological malignancies and the need for careful monitoring and reevaluation, particularly in patients with persistent cytopenias.
